Evidence map›Paper›PMID 36028281›Full record

ArticleJournal for immunotherapy of cancer2022

Chemical priming of natural killer cells with branched polyethylenimine for cancer immunotherapy.

Seung Hee Choi, Hye Jin Kim, Joo Dong Park, Eun-Su Ko, Minwook Lee, Dae-Keum Lee, Jin-Ho Choi, Hye Jung Jang, Isaac Kim, Hae-Yun Jung and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Journal for immunotherapy of cancer · 2023
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Seung Hee Choi *Department of Biomedical Science, CHA University, Seongnam-si, Korea (the Republic of).ORCID 0000-0002-0615-4313
Hye Jin Kim *Department of Biomedical Science, CHA University, Seongnam-si, Korea (the Republic of).
Joo Dong ParkDepartment of Biomedical Science, CHA University, Seongnam-si, Korea (the Republic of).ORCID 0000-0002-8736-7969
Eun-Su KoDepartment of Biomedical Science, CHA University, Seongnam-si, Korea (the Republic of).ORCID 0000-0002-6131-878X
Minwook LeeDepartment of Biomedical Science, CHA University, Seongnam-si, Korea (the Republic of).
Dae-Keum LeeDepartment of Biomedical Science, CHA University, Seongnam-si, Korea (the Republic of).
Jin-Ho ChoiDepartment of Biomedical Science, CHA University, Seongnam-si, Korea (the Republic of).
Hye Jung JangDepartment of Biomedical Science, CHA University, Seongnam-si, Korea (the Republic of).
Isaac KimDepartment of Surgery, Bundang CHA Medical Center, CHA University, Seongnam-si, Korea (the Republic of).
Hae-Yun JungDepartment of Biomedical Science, CHA University, Seongnam-si, Korea (the Republic of).
Keun-Hong ParkDepartment of Biomedical Science, CHA University, Seongnam-si, Korea (the Republic of) pkh0410@cha.ac.kr kspark@cha.ac.kr.
Kyung-Soon ParkDepartment of Biomedical Science, CHA University, Seongnam-si, Korea (the Republic of) pkh0410@cha.ac.kr kspark@cha.ac.kr.
CHA University · KRCHA University Bundang Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDue to their powerful immune surveillance activity and ability to kill and clear cancer cells, natural killer (NK) cells are an emerging anticancer immunotherapeutic agent. Therefore, there is much interest in developing efficient technologies that further enhance the therapeutic antitumor efficacy of NK cells.

methodsTo produce chemically primed NK cells, we screened polymers with various electric charges and examined their ability to enhance the cytotoxicity of NK cells. The effect of primary amine and electric charges of 25 kDa branched polyethylenimine (25KbPEI) was investigated by fluorination of the chemical. The role of 25KbPEI in determining the major priming mechanism was investigated in terms of calcium influx into NK cells. In vivo therapeutic efficacy of chemically primed NK cells was evaluated against solid tumor mouse model of triple negative breast and ovarian cancers.

resultsChem_NK that was produced by the priming activity of 25KbPEI showed potent antitumor activity to various cancer cells. Chem_NK showed an activated phenotype, which manifests as increased expression of activating/adhesion/chemokine receptors and perforin accumulation, leading to enhanced migration ability and antitumor activity. Chem_NK display potent therapeutic efficacy against in vivo mouse model of triple negative breast and ovarian cancers. Fluorination of the primary amine group reduces the activity of 25KbPEI to prime NK cells, indicating that the cationic charge on the chemical plays a critical role in NK cell activation. A major priming mechanism was 25KbPEI-mediated calcium influx into NK cells, which occurred mainly via the Ca2

conclusionsNK cells can be chemically primed with 25KbPEI to express potent antitumor activity as well as enhanced migration ability. Because PEI is a biocompatible and Food and Drug Administration-approved chemical for biomedical use, these results suggest a cost-effective and simple method of producing therapeutic NK cells.

Indexed as

Antineoplastic AgentsOvarian NeoplasmsTriple Negative Breast NeoplasmsAminesAnimalsCalciumCell Line, TumorFemaleHumansImmunotherapyKiller Cells, NaturalMicePolyethyleneimineUnited StatesAminesAntineoplastic AgentsCalciumPolyethyleneimineimmunity, cellularimmunotherapykiller cells, natural

Identifiers

PMID36028281
PMCPMC9422841
OpenAlexW4293124440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.